• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy
  • Reports
    • Diabetes Technology Innovations Special Report
    • Continuous Glucose Monitoring (CGM) Market Report

Glucotrack has more data backing implantable glucose monitor, plans for human trials this year

June 6, 2024 By Sean Whooley

GlucoTrackGlucotrack announced the completion of a second long-term preclinical study for its implantable continuous blood glucose monitor (CBGM).

The study further validates the CBGM’s sustained accuracy, the company says. It demonstrated a mean absolute relative difference (MARD) — a measurement of CGM accuracy — of 4.7% at day 90.

MARD measures the average difference between the CBGM device’s measurement and a reference measurement. Lower values indicate better performance.

Glucotrack’s CBGM measures glucose in the blood without the lag time associated with subcutaneous sensors measuring glucose in interstitial fluid. It directly measures blood glucose in real time and on a continuous basis. The company says this enables a less burdensome approach to glucose monitoring over extended periods of time.

The 90-day preclinical study included a larger number of animal subjects and a longer duration than the company’s initial 60-day study. It incorporated periodic glucose tolerance testing to compare the performance of the Glucotrack CBGM against a commercially available blood glucose monitor and a subcutaneous CGM. The company said it completed the study with no significant adverse effects.

Glucotrack plans to initiate human clinical trials later this year.

“We are again very pleased with the performance of our sensor during a long-term preclinical study and look forward to moving into human clinical trials,” said Paul Goode, CEO of Glucotrack. “Our CBGM’s ability to continuously measure blood glucose for 2+ years with accuracy, minimal calibration and without a wearable device represents a significant advancement in glucose monitoring. We believe this technology has the potential to greatly improve the quality of life for people with diabetes by providing a more convenient and discreet monitoring solution.”

Filed Under: Clinical Trials, Diabetes, Featured, Implants, Patient Monitoring Tagged With: Glucotrack

IN CASE YOU MISSED IT

  • MiniMed claims quick FDA clearance for Fit patch pump
  • Tandem’s Mobi pump wins FDA clearance for 7-day tubeless wearable set
  • Senseonics delivers ‘breakout quarter’ more than doubling Eversense 365 revenue
  • Tandem Diabetes Care names successor as CEO Sheridan retires
  • MiniMed names new CMO ahead of planned retirement

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.
MDO

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
About
Contact us
Listen to our Weekly Podcasts
Advertise

Copyright © 2026 · Arrowfly LLC. All Rights Reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy | Terms & Conditions | RSS